← Back to Search

Reinvention Therapy for Multiple Sclerosis

N/A
Recruiting
Research Sponsored by Kessler Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18 years of age or older
Diagnosis of multiple sclerosis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 6 months
Awards & highlights

Study Summary

This trialaims to develop and test an intervention to improve quality of life for people with MS. It includes focus groups and a randomized controlled trial.

Who is the study for?
This trial is for adults over 18 who speak English, can consent, have internet access, and are diagnosed with multiple sclerosis. It's not for those with other medical or psychological conditions that could interfere with participation, live too far away (over 50 miles) for in-person sessions, or have cognitive impairments.Check my eligibility
What is being tested?
The study tests 'Reinventing Yourself with MS', an adaptation of a program originally designed for spinal cord injury. The focus is on improving quality of life by addressing personal factors like self-efficacy through two phases: focus groups to tailor the intervention and a randomized controlled trial to test its effectiveness.See study design
What are the potential side effects?
Since this intervention involves non-medical techniques aimed at lifestyle modification and coping strategies rather than drugs or medical procedures, traditional side effects are not applicable. However, participants may experience emotional discomfort discussing personal issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have been diagnosed with multiple sclerosis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
General Self-Efficacy Scale
Multiple Sclerosis Self-Efficacy Scale
Secondary outcome measures
Benefit Finding in Multiple Sclerosis Scale
Chicago Multiscale Depression Inventory
Connor-Davidson Resilience Scale
+6 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Group InterventionExperimental Treatment1 Intervention
Participants will attend six weekly two-hour facilitator-led sessions that include didactic presentations of eight core skills and related experiential exercises with extensive group discussion. These skills are presented in sequence over the course of the intervention so that participants can gain mastery of introductory concepts before undertaking those that are both more difficult and complex. The culmination of developing these skills and participation in a peer group will assist individuals in increasing self-efficacy and overall QOL, well-being and participation. Participants will complete follow-up assessment at 18- and 30-weeks post-intervention.
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive no intervention throughout the course of the study; however, the participants will be tested at 18- and 30-weeks participation in the study.

Find a Location

Who is running the clinical trial?

Craig HospitalOTHER
39 Previous Clinical Trials
8,296 Total Patients Enrolled
2 Trials studying Multiple Sclerosis
154 Patients Enrolled for Multiple Sclerosis
Kessler FoundationLead Sponsor
172 Previous Clinical Trials
10,615 Total Patients Enrolled
32 Trials studying Multiple Sclerosis
1,569 Patients Enrolled for Multiple Sclerosis
University of MinnesotaOTHER
1,371 Previous Clinical Trials
1,588,033 Total Patients Enrolled
5 Trials studying Multiple Sclerosis
889 Patients Enrolled for Multiple Sclerosis

Media Library

Reinvention with MS Clinical Trial Eligibility Overview. Trial Name: NCT05195320 — N/A
Multiple Sclerosis Research Study Groups: Placebo, Group Intervention
Multiple Sclerosis Clinical Trial 2023: Reinvention with MS Highlights & Side Effects. Trial Name: NCT05195320 — N/A
Reinvention with MS 2023 Treatment Timeline for Medical Study. Trial Name: NCT05195320 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the aggregate total of participants involved in this experiment?

"Affirmative. Evidenced on clinicaltrials.gov, the trial which was inaugurated on August 1st 2022 is currently recruiting individuals for participation. The research requires 48 volunteers to be sourced from a single locale."

Answered by AI

Are there still spots available in this medical study?

"Affirmative. According to clinicaltrials.gov, the research project that was first made available on August 1st 2022 is currently recruiting patients. 48 individuals need to be enlisted from a single medical centre for this trial."

Answered by AI

What positive effects is this study attempting to achieve?

"This clinical trial's main objective is to evaluate patients' self-efficacy in managing multiple sclerosis, over a 6 month period. Secondary goals include quantifying their quality of life and participation levels via the Health Status Questionnaire, Ryff Psychological Wellbeing Scales, and Participation Assessment with Recombined Tools-Objective (PART-O)."

Answered by AI

Who else is applying?

How old are they?
18 - 65
What site did they apply to?
Kessler Foundation
What portion of applicants met pre-screening criteria?
Met criteria
~12 spots leftby Sep 2024